Cardiovascular dysfunction becomes recognized as a risk for dementia. In this issue of Neuron, Park et al. (2018) report the age-related, brain endothelial-specific upregulation of acid sphingomyelinase (ASM), leading to blood-brain barrier malfunction, neurodegeneration, and memory deficits that were mitigated by ASM inhibition in mice.
Age-related neurodegeneration and dementia, leading to substantial individual disabilities and socio-economic complications, become more prevalent due to the demographic aging of Western societies. Although appropriate therapeutic targets to prevent neurodegeneration are missing, cardiovascular risk factors have been shown to strongly correlate with dementia (O'Brien and Markus, 2014) . Given the neat interaction between the vascular compartment and the cells of the brain parenchyma, forming the neurovascular unit (NVU), neurodegenerative diseases frequently coincide with blood-brain barrier (BBB) impairment (Liebner et al., 2018) . In the context of aging and dementia, multiple pathways appear to be regulated, including lipid metabolism that is in part controlled by sphingomyelinases (neutral and acid sphingomyelinase; NSM and ASM), conferring the enzymatic conversion of sphingomyelin, an abundant membrane component, into ceramide that is involved in the regulation of cell survival, proliferation, and differentiation, as well as of senescence and apoptosis (Chung et al., 2016) .
The manuscript by Park et al. (2018) in this issue of Neuron shows the upregulation of ASM in human and mouse plasma and, specifically, in brain vessels during aging, comparing 3-and 20-month-old mice. Endothelial ASM upregulation in mice coincides with reduced vascular density, branching, and BBB impairment evidenced by increased leakage of differently sized tracers, which was significantly rescued in mice by haploid ASM gene deletion (Smpd1 +/À ). Park et al. (2018) further show that junctions appear to be unaffected in stainings for junction proteins and by electron microscopy (EM). Instead, they report a significant increase in vesicle formation in brain endothelial cells (ECs), coinciding with augmented protein expression of phosphorylated caveolin-1 (P-Cav-1), a major component of the caveolae type of vesicles involved in luminal to abluminal transport of blood-borne substances. Interestingly, vascular permeability did not necessarily overlap with the pattern of endothelial apoptosis and string-like vessels, suggesting that EC death was not the prime reason for BBB impairment. Nevertheless, it might be illuminating to investigate metabolites downstream of ceramide, such as sphingosine-1-phosphate (S1P), which was shown to modulate BBB function.
Importantly, analyzing neuronal density by NeuN staining, brain diameter, and spine density by EM and synaptophysin staining in the hippocampal CA1 region, Park et al. (2018) demonstrate that the functional impairment of the BBB by increased Cav-1-mediated transcytosis in aged mice results in decreased cognitive performance, which was partially rescued in Smpd1 +/À mice. Moreover, learning and memory, fear conditioning, and electrophysiological long-term potentiation (LTP) revealed decreased abilities in aged mice that were again partially rescued in the age-matched Smpd1 +/À transgenics.
Mechanistically, Park et al. (2018) show that ASM treatment had no effect on early cell viability by inducing cell death through the ceramide pathway but increased the formation of vesicles in mouse brain ECs in vitro. ASM treatment of ECs lead to increased permeability of 4kDa dextran and Alexa488-BSA (bovine serum albumin), but no differences in Alexa488-Tfn (transferrin) and transendothelial electrical resistance (TEER), which are measures for clathrin-mediated transport and paracellular permeability/junctional integrity, respectively. Moreover, ASM treatment lead to the downregulation of BBB-related efflux transporters like BCRP (breast cancer resistance protein, ABCG2) and MDR1 (multi-drug resistance protein 1, P-glycoprotein, ABCB1A), mediated by augmented internalization and lysosomal degradation. This effect was abrogated in Cav-1-deficient ECs or treatment with a caveolae-disrupting drug. Park et al. (2018) provide further evidence that ASM results in the disorganization of the cytoskeleton by a mechanism involving PP1-mediated ERM (ezrin, radixin, moesin) dephosphorylation, augmenting caveolae internalization leading to endothelial hyperpermeability ( Figure 1 ).
Then Park et al. (2018) addressed the consequence of brain endothelial-specific ASM overexpression, using a Cre-lox approach (Slco1c1-Cre ERT2 ;Smpd1 ox/ox ). Overexpression of ASM in brain ECs resulted in accelerated BBB dysfunction, which already became apparent at 13 months of age as opposed to 20 months in wild-type (WT) mice. ASMoverexpressing mice revealed comparable BBB, vascular, neuronal, and cognitive effects as observed in 20-month-old WT mice, suggesting that endothelial-specific overexpression of ASM is sufficient to induce the age-related BBB defects, leading to dementia.
This encouraged Park et al. (2018) to counteract ASM overexpression in Slco1c1-Cre ERT2 ;Smpd1 ox/ox mice by Smpd1 miRNA RNAi, expressed under the endothelial-specific endoglin promotor, which resulted in a reduction of Cav-1 phosphorylation and caveolae formation but in decreased tracer permeability. Along with reduced ASM activity, RNAi treatment rescued neuronal density and cognitive performance. These results were, in principle, corroborated in Slco1c1-Cre ERT2 ;Smpd1 ox/ox mice treated with the ASM inhibitor amitriptyline-hydrochloride (AMI), which is an FDA-approved antidepressant.
The work by Park et al. (2018) highlights an interesting, age-related upregulation of ASM in brain ECs, leading to increased vascular permeability, and BBB breakdown via augmented caveolae-mediated vesicular transport (Figure 1) . As molecular mediators of age-related BBB breakdown have not consistently been described until now, the finding by Park and colleagues is highly relevant for the strategic development of anti-aging and -dementia thera-pies. Given the intriguing finding that ASM inhibition by AMI has beneficial effects on BBB function and cognitive performance, it should be emphasized that the administration of this FDA-approved drug is associated with side effects like hypotension, arrhythmias, and other cardiovascular complications (Zemrak and Kenna, 2008) . Therefore, as discussed by Park et al. (2018) , it is worth investing in the development of novel, specific ASM inhibitors with less offtarget effects.
A major question that remains to be addressed is which regulators are upstream of endothelial ASM during aging. The role of ASM on the release of extracellular vesicles (EVs) by red blood cells (RBCs) and other cell types has already been described (Bianco et al., 2009) . Given the apparent parallels, it might be promising to test the already described upstream pathway controlling ASM-directed EV release by other cell types in the context of aged ECs. In astrocytes (ACs), a NVU cell with a substantial expression level of ASM (Vanlandewijck et al., 2018) , and other cell types, like microglia and T cells, EV release is mediated by ATP binding to the P2X 7 receptor, which activates phosphorylation of P38 MAP kinase (MAPK) through src-protein tyrosine kinase. Phosphorylated P38 MAPK induces translocation of ASM from the lysosomes to the plasma membrane, where it induces perturbations of the membrane, favoring budding of EVs. In myeloid or lymphoid cells, the P2X 7 receptor functions as an ATP-gated non-selective cation channel and its activation shapes the intensity or duration of innate immune and inflammatory responses (Bianco et al., 2009) . In this regard, it is interesting to note that chronic inflammation, known as ''inflammeageing,'' is one of the hallmarks of aging (Ferrucci and Fabbri, 2018) . Along this line, it was demonstrated that ''ASM promotes endothelial stress response in systemic inflammation and sepsis'' (Chung et al., 2016) . Interestingly, Park et al. (2018) show that aged mice upregulate ICAM-1 in ECs (see Figure 2L ), suggesting that in the mouse model employed, inflammeageing could be observed. Moreover, TNF-a was previously shown to induce ICAM-1 expression in ECs, which in turn are prone to leukocyte extravasation (Liebner et al., 2018) .
In light of the publication by Park et al. (2018) , another interesting aspect worth exploring in the future would be to understand the relation of ASM expression and more specific forms of dementia, such as vascular and Alzheimer's dementia (AD). As Park et al. (2018) discuss in the manuscript, BBB impairment has been controversially discussed in the context of aging and, in particular, in the context of AD. Although there is ample evidence for a correlation of cardiovascular risk factors and dementia so far, a direct role of the vasculature in dementia formation has been missing (Sweeney et al., 2018) . Clearly, the publication by Park and colleagues focuses on aging and does not touch the role of ASM in AD (Park et al., 2018) . However, previous work by the same group has suggested that ASM modulates the autophagic process in non-ECs by controlling lysosomal 
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Previews biogenesis in AD (Lee et al., 2014) . Lee et al. (2014) show that also in an AD mouse model, heterozygosity of Smpd1 partially rescued cognitive decline, which might be-in light of the novel data-a combined effect of endothelial-specific and non-endothelial-specific (astrocytic, pericytic, and/or neuronal) lowering of ASM expression ( Figure 1) . Therefore, when considering therapeutic control of ASM, the cellular compartments and regulation of cell-specific pathways have to be taken into account, which remains a challenge for targeted therapy.
As mentioned above, astrocytic endfeet are an essential part of the NVU and recently, single-cell RNA-seq analysis of healthy, young adult WT mice indicated that ASM is most prominently expressed in ACs of the NVU (Vanlandewijck et al., 2018) . Given the statistically significant elevation of ASM in microvessel-depleted aged brain and the lack of AC characterization, an endothelial-exclusive role in ASM increase during aging might not be the case.
In conclusion, the finding by Park et al. (2018) is highly relevant for future therapeutic strategies to counteract vascular aging in the CNS and ultimately dementia. It presents convincing evidence for a crucial role of ASM for vascular homeostasis and dementia, supporting the saying ''we are just as old as our vessels.'' When infection spreads in the body, organs suffer. In some circumstances, brain inflammation may develop from infection and affect neuronal functions (Klein et al., 2017) . Understanding of the precise sequence of cellular and molecular events that occur in the brain after infection could guide the development of treatments to limit brain damage. Glial cells, mainly microglia and astrocytes, are key players in neuroinflammation. The resident immune cells of the nervous system, microglia are considered first responders. Microglia have motile processes that constantly survey the parenchyma and physically respond to local injury within minutes (Davalos et al., 2005; Nimmerjahn et al., 2005) . Both microglia and astrocytes contribute to acute and chronic inflammation by proliferating and releasing immune factors, such as cytokines and chemokines. For example, in response to systemic lipopolysaccharide (LPS) administration to model bacterial infection, microglia become activated with delayed directed process motility and repress hippocampal neurogenesis (Gyoneva et al., 2014; Monje et al., 2003) . Systemic infection may compromise the integrity of the blood-brain barrier (BBB), which is regulated by endothelial cell tight junctions, astrocytic endfeet, microglia, and pericytes that together restrict the passage of plasma proteins and cells into the brain. In most studies, the effects of
